Quince Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Apr 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $5.5M | — | — | $6.8M | — | — | $8.1M |
| SG&A Expense | — | $16.6M | — | — | $4.3M | — | — | $3.3M |
| Operating Income | — | $-79.8M | — | — | $-14.6M | — | — | $-13.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $75.0K | — | — | $-5.3M | — | — | $-46.0K |
| Net Income | — | $-75.5M | — | — | $35.9M | — | — | $-13.4M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-12.31 | — | — | $3.60 | — | — | $-0.25 |
| EPS (Diluted) | — | $-12.31 | — | — | $2.88 | — | — | $-0.25 |
| Shares Outstanding (Basic) | 1.0M | 6.1M | 16.3M | 163.0M | 9.1M | 278.6K | 55.7M | 54.0M |
| Shares Outstanding (Diluted) | 1.0M | 6.1M | 16.3M | 163.0M | 9.2M | 278.6K | 55.7M | 54.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |